WXFL 10030390
Alternative Names: WX 390; WXFL10030390Latest Information Update: 02 Jan 2025
At a glance
- Originator Cisen Pharmaceutical; Shanghai Jiatan Pharmatech
- Developer Shanghai Jiatan Pharmatech
- Class Antineoplastics; Pyrimidinones; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adenocarcinoma; Solid tumours
- No development reported Lymphoma
Most Recent Events
- 13 Sep 2024 Efficacy and adverse events data from a phase II trial in Solid tumors presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
- 13 Sep 2024 Efficacy and adverse events data from a phase Ib/IIa trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
- 13 Sep 2024 Pharmacodynamics data from a preclinical trial in Solid tumors presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)